FDA Leader Joins Quintiles Transnational's Regulatory Group
RESEARCH TRIANGLE PARK, N.C., Aug. 2 /PRNewswire-FirstCall/ -- Quintiles Transnational Corp. today announced the appointment of an expert in the regulation of pharmaceutical and biotechnology products, Edward Tabor, M.D., as Executive Director, Regulatory & Technical Services.
Dr. Tabor joins Quintiles from the FDA, where he created the antiviral regulatory review program in the 1980s and most recently served as Associate Director for Medical Affairs in the Office of Blood Research and Review, in the Center for Biologics Evaluation and Research (CBER). He also has served as Associate Director, Biological Carcinogenesis, National Cancer Institute, at the National Institutes of Health (NIH).
"Dr. Tabor has played a leading role in the regulatory oversight of pharmaceutical and biotechnology product review, particularly in virology, and his experience and expertise will be a great asset for us," said David Frakes, M.D., Vice President, Medical Affairs, CDS Americas. "His leadership skills and extensive knowledge of the regulatory process adds significantly to the strength of our team of 20 physicians in Medical Affairs, particularly in designing clinical trial programs."
At Quintiles, Dr. Tabor leads the regulatory consulting group for North America, providing strategic regulatory advice to pharmaceutical and biotechnology customers. He also provides regulatory support to Quintiles' strategic investment group, PharmaBio Development. He is located at the Quintiles office in Rockville, Md.
"The appointment of Dr. Tabor is especially good news for Quintiles' emerging biotechnology customers," said Chip Gillooly, Global Vice President of Emerging Biotechnology. "They recognize that sound regulatory advice early in the development of a clinical program is crucial to the most efficient use of their limited resources. Dr. Tabor and his team are ready to help."
From 1983-1988, Dr. Tabor was Director of the FDA Division of Anti- Infective Drug Products. Under his leadership, the division reviewed and approved AZT, the first treatment for human immunodeficiency virus (HIV). He led the development of the antiviral regulatory policy and created an anti- viral review group that formed the basis of a separate FDA Division of Antiviral Drug Products.
From 1988-1995, he served as Associate Director for Biological Carcinogenesis in the NIH's National Cancer Institute, supervising six research laboratories. He returned to FDA in 1995 as Director of the Division of Transfusion Transmitted Diseases.
He received his bachelor's degree from Harvard College in Cambridge, Mass., and his M.D. from the Columbia University College of Physicians & Surgeons in New York City. He was an intern and resident at Babies Hospital in Columbia-Presbyterian Medical Center in New York City.
About Quintiles
Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, Quintiles has offices in 50 countries and is the world's leading pharmaceutical services organization. For more information visit the company's Web site at http://www.quintiles.com.
Quintiles Transnational Corp.CONTACT: Dick Jones, Media Relations, +1-919-998-2091, ormedia.info@quintiles.com , or Greg Connors, Investor Relations,+1-919-998-2000, or invest@quintiles.com , both of Quintiles TransnationalCorp.
Web site: http://www.quintiles.com/